Adalimumab Solution for Injection

Description

Product Overview

Adalimumab Solution for Injection is a recombinant fully human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), an important inflammatory cytokine involved in numerous chronic immune-mediated disorders. As a biosimilar developed under strict quality standards, it is designed to offer comparable quality, efficacy, and safety to the reference adalimumab product while improving patient access to biologic therapy.

The product is manufactured in GMP-compliant facilities with comprehensive quality control and batch consistency, making it suitable for pharmaceutical distributors, healthcare institutions, and international partners seeking reliable biologic solutions.

Key Features

• Fully human anti-TNF-α monoclonal antibody

• Biosimilar developed through rigorous analytical and clinical comparability studies

• Comparable efficacy, safety, and immunogenicity to the reference product

• Manufactured under international GMP quality management systems

• Stable formulation with consistent product quality

• Suitable for long-term treatment of multiple autoimmune diseases

• Supports broader patient accessibility to biologic therapies

Mechanism of Action

Adalimumab specifically binds to TNF-α, preventing it from interacting with TNF receptors on cell surfaces. By neutralizing TNF-α activity, the drug helps suppress inflammatory responses, reduce tissue damage, relieve clinical symptoms, and improve physical function in patients with chronic inflammatory diseases.

Therapeutic Indications

Adalimumab Solution for Injection may be indicated for the treatment of:

• Rheumatoid Arthritis (RA)

• Ankylosing Spondylitis (AS)

• Psoriatic Arthritis (PsA)

• Plaque Psoriasis

• Crohn's Disease (CD)

• Pediatric Crohn's Disease

• Ulcerative Colitis (subject to local regulatory approval)

• Juvenile Idiopathic Arthritis (JIA)

• Pediatric Plaque Psoriasis

• Non-infectious Uveitis

Indications may vary according to country-specific regulatory approvals.

Product Specifications

Manufacturing Advantages

• Advanced recombinant antibody production technology

• High-purity biologic manufacturing process

• Comprehensive quality assurance from raw materials to finished product

• GMP-certified production facilities

• Strict validation of manufacturing consistency

• Reliable global supply capability

Applications

Adalimumab Solution for Injection is suitable for:

• Hospitals and healthcare providers

• Pharmaceutical distributors

• Government procurement programs

• International pharmaceutical partners

• Medical institutions specializing in autoimmune diseases

• Biopharmaceutical importers

Packaging & Supply

• Standard commercial packaging

• Bulk supply available for international markets

• OEM/Private Label cooperation subject to regional regulations

• Professional export documentation support

Why Choose Our Adalimumab Solution for Injection?

• High-quality biosimilar manufactured under stringent international standards

• Reliable production capacity with stable supply

• Comprehensive quality management throughout manufacturing

• Competitive global partnership opportunities

• Technical and regulatory support for international markets

Recommended Applications

Adalimumab Solution for Injection provides an effective biologic treatment option for patients requiring long-term management of chronic inflammatory and autoimmune diseases. Through targeted inhibition of TNF-α, it contributes to disease control, symptom improvement, and enhanced quality of life while supporting wider access to advanced biologic therapies.

Note: This product information is intended for healthcare professionals and pharmaceutical business partners. Product availability, approved indications, and labeling may differ by country or region according to local regulatory requirements.